Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin.
| Title: | Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin. |
|---|---|
| Authors: | de Gooyer JM; Department of Medical Imaging, Nuclear medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. jan-marie.gooyer@radboudumc.nl.; Department of Surgery Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. jan-marie.gooyer@radboudumc.nl.; Elekonawo FMK; Department of Medical Imaging, Nuclear medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; Department of Surgery Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; Bremers AJA; Department of Surgery Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; Boerman OC; Department of Medical Imaging, Nuclear medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; Aarntzen EHJG; Department of Medical Imaging, Nuclear medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; de Reuver PR; Department of Surgery Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; Nagtegaal ID; Department of pathology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; Rijpkema M; Department of Medical Imaging, Nuclear medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.; de Wilt JHW; Department of Surgery Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. |
| Source: | Nature communications [Nat Commun] 2022 May 12; Vol. 13 (1), pp. 2621. Date of Electronic Publication: 2022 May 12. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : Nature Pub. Group |
| MeSH Terms: | Colorectal Neoplasms*/diagnostic imaging ; Colorectal Neoplasms*/pathology ; Colorectal Neoplasms*/surgery ; Peritoneal Neoplasms*/diagnostic imaging ; Peritoneal Neoplasms*/secondary ; Peritoneal Neoplasms*/surgery; Cytoreduction Surgical Procedures/methods ; Optical Imaging/methods ; Antibodies, Monoclonal ; Carcinoembryonic Antigen ; Humans |
| Abstract: | In patients with colorectal peritoneal metastases scheduled for cytoreductive surgery, accurate preoperative estimation of tumor burden and subsequent intraoperative detection of all tumor deposits remains challenging. In this study (ClinicalTrials.gov NCT03699332) we describe the results of a phase I clinical trial evaluating [111In]In-DOTA-labetuzumab-IRDye800CW, a dual-labeled anti-carcinoembryonic antigen (anti-CEA) antibody conjugate that enables both preoperative imaging and intraoperative radioguidance and fluorescence imaging. Primary study outcomes are safety and feasibility of this multimodal imaging approach. Secondary outcomes are determination of the optimal dose, correlation between tracer uptake and histopathology and effects on clinical strategy. Administration of [111In]In-DOTA-labetuzumab-IRDye800CW is well-tolerated and enables sensitive pre- and intraoperative imaging in patients who receive 10 or 50 mg of the tracer. Preoperative imaging revealed previously undetected lymph node metastases in one patient, and intraoperative fluorescence imaging revealed four previously undetected metastases in two patients. Alteration of clinical strategy based on multimodal imaging occurred in three patients. Thus, multimodal image-guided surgery after administration of this dual-labeled tracer is a promising approach that may aid in decision making before and during cytoreductive surgical procedures.; (© 2022. The Author(s).) |
| Comments: | Comment in: Radiol Imaging Cancer. 2022 Sep;4(5):e229021. doi: 10.1148/rycan.229021.. (PMID: 36178352) |
| References: | Lancet Oncol. 2021 Feb;22(2):256-266. (PMID: 33476595); J Nucl Med. 2019 Mar;60(3):418-423. (PMID: 30630938); BJS Open. 2019 Jun 27;3(5):585-594. (PMID: 31592510); Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772); Ann Surg Oncol. 2008 Sep;15(9):2426-32. (PMID: 18521686); Cancer Treat Res. 1996;82:359-74. (PMID: 8849962); Mol Imaging Biol. 2010 Dec;12(6):583-94. (PMID: 20376568); Nat Med. 2011 Sep 18;17(10):1315-9. (PMID: 21926976); Ann Surg Oncol. 2015 Apr;22(4):1236-42. (PMID: 25319584); J Clin Oncol. 2010 Jan 1;28(1):63-8. (PMID: 19917863); Lancet Gastroenterol Hepatol. 2016 Dec;1(4):283-290. (PMID: 28404198); Dis Colon Rectum. 2017 Apr;60(4):368-375. (PMID: 28267003); Ann Surg Oncol. 2009 Feb;16(2):327-33. (PMID: 19050972); Ann Surg Oncol. 2018 Jul;25(7):1992-2001. (PMID: 29671139); Br J Surg. 2013 Jan;100(2):285-92. (PMID: 23124619); J Clin Oncol. 2017 Oct 10;35(29):3338-3346. (PMID: 28817371); Biomark Cancer. 2016 Sep 27;8:119-133. (PMID: 27721658); World J Surg. 2015 Feb;39(2):453-60. (PMID: 25245434); Dig Surg. 2021;38(3):205-211. (PMID: 33657551); Abdom Radiol (NY). 2020 Feb;45(2):301-306. (PMID: 31642963); Cancers (Basel). 2020 Apr 17;12(4):. (PMID: 32316388); Clin Colorectal Cancer. 2002 May;2(1):31-42. (PMID: 12453334); Theranostics. 2018 Mar 8;8(8):2161-2170. (PMID: 29721070); Nat Commun. 2020 Nov 9;11(1):5667. (PMID: 33168818); Lancet Gastroenterol Hepatol. 2018 Mar;3(3):181-191. (PMID: 29361435); Eur J Surg Oncol. 2018 Aug;44(8):1241-1246. (PMID: 29739638); Mol Diagn Ther. 2020 Apr;24(2):191-200. (PMID: 32048177); Br J Surg. 2012 May;99(5):699-705. (PMID: 22287157); Ann Surg Oncol. 2016 May;23(5):1461-7. (PMID: 26542584); Eur J Surg Oncol. 2005 Jun;31(5):540-3. (PMID: 15922890); Biomark Cancer. 2017 Aug 28;9:1179299X17728254. (PMID: 28874886); J Nucl Med. 2014 Sep;55(9):1519-24. (PMID: 24982436); Onco Targets Ther. 2018 Mar 23;11:1655-1664. (PMID: 29615840); Br J Cancer. 2013 Feb 19;108(3):662-7. (PMID: 23322207); Ann Surg Oncol. 2020 Apr;27(4):1084-1093. (PMID: 31641950) |
| Molecular Sequence: | ClinicalTrials.gov NCT03699332 |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal); 0 (Carcinoembryonic Antigen) |
| Entry Date(s): | Date Created: 20220513 Date Completed: 20220517 Latest Revision: 20221013 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9098887 |
| DOI: | 10.1038/s41467-022-29630-9 |
| PMID: | 35551444 |
| Database: | MEDLINE |
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't